Mohit Bansal
Stock Analyst at Wells Fargo
(4.24)
# 388
Out of 5,162 analysts
199
Total ratings
65.79%
Success rate
9.31%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Overweight | $135 → $150 | $115.91 | +29.41% | 14 | Mar 12, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $235 → $250 | $180.32 | +38.64% | 4 | Feb 25, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $65 → $75 | $63.56 | +18.00% | 8 | Feb 19, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $325 → $375 | $367.79 | +1.96% | 13 | Feb 19, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $70 → $75 | $59.07 | +26.97% | 7 | Feb 18, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $180 → $175 | $127.78 | +36.95% | 8 | Feb 13, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $150 → $165 | $145.21 | +13.63% | 14 | Feb 11, 2026 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $200 | $184.90 | +8.17% | 16 | Feb 9, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $55 → $60 | $58.95 | +1.78% | 11 | Feb 6, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,200 → $1,280 | $977.25 | +30.98% | 19 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $745 → $800 | $746.61 | +7.15% | 22 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $5 | $3.38 | +47.93% | 6 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $1.75 | +357.14% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $515 | $478.13 | +7.71% | 12 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $26.99 | +103.78% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $225.37 | +15.37% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $35 | $27.55 | +27.04% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $90.10 | +66.48% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $57.90 | -18.83% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $15.46 | +94.05% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $41.17 | +70.03% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $26.86 | +11.69% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $27.12 | +6,813.72% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $6.13 | +487.28% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $7.90 | +140.51% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.13 | +5,209.73% | 4 | Dec 3, 2019 |
Merck & Co.
Mar 12, 2026
Maintains: Overweight
Price Target: $135 → $150
Current: $115.91
Upside: +29.41%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $235 → $250
Current: $180.32
Upside: +38.64%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $65 → $75
Current: $63.56
Upside: +18.00%
Amgen
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $325 → $375
Current: $367.79
Upside: +1.96%
BioMarin Pharmaceutical
Feb 18, 2026
Maintains: Overweight
Price Target: $70 → $75
Current: $59.07
Upside: +26.97%
Neurocrine Biosciences
Feb 13, 2026
Maintains: Overweight
Price Target: $180 → $175
Current: $127.78
Upside: +36.95%
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $150 → $165
Current: $145.21
Upside: +13.63%
Biogen
Feb 9, 2026
Maintains: Equal-Weight
Price Target: $190 → $200
Current: $184.90
Upside: +8.17%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $55 → $60
Current: $58.95
Upside: +1.78%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,200 → $1,280
Current: $977.25
Upside: +30.98%
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $745 → $800
Current: $746.61
Upside: +7.15%
Jan 5, 2026
Maintains: Equal-Weight
Price Target: $3 → $5
Current: $3.38
Upside: +47.93%
Dec 16, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $1.75
Upside: +357.14%
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $478.13
Upside: +7.71%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $26.99
Upside: +103.78%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $225.37
Upside: +15.37%
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $27.55
Upside: +27.04%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $90.10
Upside: +66.48%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $57.90
Upside: -18.83%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $15.46
Upside: +94.05%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $41.17
Upside: +70.03%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $26.86
Upside: +11.69%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $27.12
Upside: +6,813.72%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $6.13
Upside: +487.28%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $7.90
Upside: +140.51%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.13
Upside: +5,209.73%